Loading stock data…
Neurocrine Biosciences, Inc. (NBIX)
$170.00+1.48 (+0.88%)
After Hours$171.20+1.20 (+0.71%)· Last close Jun 29
Neurocrine Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neurocrine Biosciences, Inc. in the Healthcare sector is trading at $170.00 with a market capitalization of $16.6B. Wall Street consensus targets $195.06 (28 analysts), implying a +14.7% move over the next 12 months. The stock is currently near its 52-week high of $171.43, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $814.50M↑ | $805.50M↑ | $794.90M↑ | $687.50M↑ | $572.60M |
| Gross Profit | $800.70M↑ | $787.90M↑ | $780.90M↑ | $676.20M↑ | $563.40M |
| Operating Income | $186.00M↓ | $227.90M↓ | $239.30M↑ | $145.60M↑ | $23.70M |
| Net Income | $197.90M↑ | $153.70M↓ | $209.50M↑ | $107.50M↑ | $7.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.40
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.62%
Volume
Today's trading volume
1.35M
Recent News
Top Stock Picks for Week of June 29, 2026
A Worldwide Provider of Semiconductor Memory Solutions Outperforming its Sector and a High-Reward Biotech Stock With Strong Earnings Momentum.
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day
Neurocrine Biosciences earns Bull of the Day on rising earnings forecasts, while Ryanair is Bear of the Day as weaker fares and cost pressures weigh on outlook.
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed?
Earlier in June 2026, Neurocrine Biosciences reported new Phase 3 and real‑world data at ENDO 2026 showing CRENESSITY improved hormone control, cardiometabolic markers, bone health and growth outcomes in classic congenital adrenal hyperplasia, with no new long‑term safety concerns. A particularly important insight is that CRENESSITY showed meaningful benefits even in the rarer 11β‑hydroxylase deficiency subtype, where clinical evidence has been scarce, while also enabling lower...
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype
Neurocrine Biosciences (NasdaqGS:NBIX) presented new long term clinical data for CRENESSITY in classic congenital adrenal hyperplasia at ENDO 2026. The data set includes Phase 3 and retrospective case series results that assess efficacy and safety outcomes. New evidence was reported in patients with the rarer 11ß-hydroxylase deficiency subtype of congenital adrenal hyperplasia. Findings relate to cardiometabolic and bone health measures and add to the clinical evidence base for...